{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:25:43Z","timestamp":1770755143688,"version":"3.50.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This review aims to highlight the different types of chemotherapy-induced cardiotoxicity and will discuss the evidence base behind the use of different cardiac biomarkers to predict cardiovascular complications. Additionally, we will review the use of cardiac biomarkers to monitor cardiac outcomes and the role of cardioprotective medications in reducing cardiovascular side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings:<\/jats:title>\n            <jats:p>Chemotherapy has been linked to an increased risk of cardiotoxicity and heart failure. Currently, patients receiving chemotherapy undergo echocardiogram before starting chemotherapy and every 6 months to monitor for any decline in cardiac function. We reviewed the current evidence and practice guidelines of monitoring chemotherapy cardiotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary:<\/jats:title>\n            <jats:p>Cardio-oncology is a rapidly evolving subspecialty in cardiology, especially with the advent of new chemotherapeutic agents, which have cardiovascular side effects. Early detection of these effects is crucial to prevent life-threatening and irreversible cardiovascular outcomes. Monitoring troponin, pro\u2013brain natriuretic peptide, and other cardiac biomarkers during chemotherapy will help to early detect cardiotoxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000314","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:43:02Z","timestamp":1692740582000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Role of Cardiac Biomarkers in Monitoring Cardiotoxicity in Chemotherapy Patients"],"prefix":"10.1097","volume":"22","author":[{"given":"Ayman","family":"Battisha","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasin","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart and Vascular Institute, West Virginia University, Morgantown, WV."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"Suppl 7","key":"R2-20250506","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines.","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R5-20250506","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"795602","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress.","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxid Med Cell Longev"},{"key":"R8-20250506","doi-asserted-by":"crossref","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","article-title":"Cardio-oncology: a focus on cardiotoxicity.","volume":"13","author":"Koutsoukis","year":"2018","journal-title":"Eur Cardiol Rev"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2796.2002.00951.x","article-title":"Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.","volume":"251","author":"Nousiainen","year":"2002","journal-title":"J Intern Med"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","article-title":"Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.","volume":"17","author":"Herman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/annonc\/mdq607","article-title":"Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?","volume":"22","author":"Verma","year":"2011","journal-title":"Ann Oncol"},{"key":"R12-20250506","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1161\/CIRCULATIONAHA.118.038529","article-title":"Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes.","volume":"139","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","article-title":"N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?","volume":"51","author":"Sandri","year":"2005","journal-title":"Clin Chem"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2011.439","article-title":"Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.","volume":"105","author":"Romano","year":"2011","journal-title":"Br J Cancer"},{"key":"R18-20250506","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","article-title":"Cardiac toxicity from systemic cancer therapy: a comprehensive review.","volume":"53","author":"Curigliano","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1373\/49.2.248","article-title":"Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy.","volume":"49","author":"Sandri","year":"2003","journal-title":"Clin Chem"},{"key":"R21-20250506","first-page":"4992","article-title":"BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.","volume":"18","author":"Lu","year":"2019","journal-title":"Oncol Lett"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250506","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"R26-20250506","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review.","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R28-20250506","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-20250506","doi-asserted-by":"crossref","first-page":"53","DOI":"10.31768\/2312-8852.2015.37(1):53-57","article-title":"The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.","volume":"37","author":"\u00dcr\u00fcn","year":"2015","journal-title":"Exp Oncol"},{"key":"R30-20250506","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","article-title":"Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).","volume":"168","author":"Ponde","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R31-20250506","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2217\/bmm.15.124","article-title":"Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?","volume":"10","author":"Chaudry","year":"2016","journal-title":"Biomark Med"},{"key":"R32-20250506","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"R33-20250506","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2013.02.007","article-title":"State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.","volume":"88","author":"Berardi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R34-20250506","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14737140.6.9.1249","article-title":"Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.","volume":"6","author":"Jones","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"R35-20250506","article-title":"Chemotherapy-induced dysfunction.","volume":"14","author":"Fern\u00e1ndez","year":"2017","journal-title":"E-J Cardiol Pract"},{"key":"R36-20250506","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","article-title":"Immunological agents used in cancer treatment.","volume":"51","author":"Simsek","year":"2019","journal-title":"Eurasian J Med"},{"key":"R37-20250506","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors.","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"R38-20250506","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients.","volume":"23","author":"Sarocchi","year":"2018","journal-title":"Oncologist"},{"key":"R39-20250506","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial.","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"key":"R40-20250506","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience.","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R41-20250506","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"R42-20250506","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T).","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:02:03Z","timestamp":1746558123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000314","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}